menu

Case Study: Life-Threatening Traumatic Bleeds and Anticoagulation Reversal in the ED

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Life-Threatening Intracranial Hemorrhage, Gastrointestinal, and Trauma-Related Bleeding in Anticoagulated Patients: Optimal Management in the Emergency Department

Case Study: Life-Threatening Traumatic Bleeds and Anticoagulation Reversal in the ED

Minute CME/CE™
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    This EMCREG-International Satellite Symposium highlights immediate interventions for three types of life-threatening bleeding in patients on an anticoagulant: intracranial hemorrhage, gastrointestinal bleeding and trauma-related bleeding. The faculty for this CME-certified event includes experts who will provide didactic and case study presentations. Plus, the faculty will also participate in an interactive panel discussion with the audience. This enduring activity was originally presented as a satellite symposium which was held during the EUSEM 2022 Congress in Berlin, Germany. 

  • Target Audience

    This program is designed to meet the educational needs of physicians involved in the care of patients with life-threatening bleeds in the presence of an anticoagulant.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the risk factors for DOAC-related bleeding, as well as the appropriate diagnosis and monitoring of a life-threatening bleed, along with the associated need for early appropriate treatment with a reversal strategy, particularly for ICH
    • Identify the appropriate diagnostic approaches to upper and lower GI bleeding, describe the essential treatment and specialist interventions, and implement treatment
    • Review the clinical applications and recommendations associated with repletion and reversal agents for DOACs, based on an understanding of the mechanism of action, benefits, risks, dosing, monitoring, and management of these agents including anti-vitamin K therapies such as coumadin, or specific direct treatments such as Factor Xa or Factor IIa anticoagulants, and describe their application to clinical practice in the management of life-threatening bleeding

  • Accreditation Statement

    Joint Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati Office of Continuing Medical Education, EMCREG-International and TotalCME, Inc.

    Physician Continuing Medical Education
    The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    The University of Cincinnati designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

  • Disclosure Statement

    Off-Label Disclosure Statement
    Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs.  Physicians should consult full prescribing information before using any product mentioned during this educational activity.

    Learner Assurance Statement
    The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity. 

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the existence of any financial interest and/or relationship(s) (e.g., paid speaker, employee, paid consultant on a board and/or committee for a commercial company) that would potentially affect the objectivity of his/her presentation or whose products or services may be mentioned during their presentation.

    The following faculty have reported relationships with ineligible companies:

    Barbara Backus, MD, PhD, faculty for this educational event, has no relevant financial relationships with ineligible companies.

    Richard Body, MB, ChB, PhD, faculty for this educational event, has received consulting fees from Abbott Point of Care, Aptamer Group, Beckman Coulter, Creavo, LumiraDx, Radiometer, Roche Diagnostics, and Siemens Healthineers.

    Martin Möckel, MD, PhD, faculty for this educational event, has received consulting fees from Alexion, Bayer Healthcare, BMS, Boehringer Ingelheim, and Daiichi Sankyo.

    W. Brian Gibler, MD, chair for this educational event, is a board member, advisor, and shareholder for Entegrion; board member and shareholder for EMCREG-International.

    All the relevant financial relationships for these individuals have been mitigated. 

  • Planners and Managers Disclosure List

    W. Brian Gibler, MD, planner for this educational event, is a board member, advisor, and shareholder for Entegrion; board member and shareholder for EMCREG-International.

    Bruce Gebhardt, MD, University of Cincinnati Reviewer for this educational event, has no relevant relationships with ineligible companies.

    Susan P. Tyler, planner for this educational event, has no relevant financial relationships with ineligible companies. 

    Barbara Forney, planner for this educational event, has no relevant financial relationships with ineligible companies. 

    Vinod Kalathiveetil, PharmD, planner for this educational event, has no relevant financial relationships with ineligible companies. 

    All the relevant financial relationships for these individuals have been mitigated. 

  • Disclaimer

    The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development. 

  • Acknowledgment

    This activity is supported by an independent educational grant from AstraZeneca.

    Jointly provided by University of Cincinnati College of Medicine Office of Continuing Medical Education, EMCREG-International, and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 11/01/2022 through 11/01/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%.
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule28 May 2023